---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-201840"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2025-09-12T23:59:59+00:00"
generated_at: "2026-05-17T06:44:21.216514+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Alkermes appoints Joshua Reed as CFO effective September 15, 2025

## Summary
- Reed will report to CEO Richard Pops and join the management committee.
- He brings 30+ years finance experience; most recently CFO of Omega Therapeutics and Aldeyra Therapeutics, and earlier at Bristol Myers Squibb.
- Base salary $615,000, target annual cash bonus 50% of base, new-hire equity grant valued at $3.5 million.
- Blair C. Jackson, EVP/COO, had been serving as interim principal financial officer; Samuel Parisi remains interim principal accounting officer.

## SEC filing metadata
- accession: 0001193125-25-201840
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2025-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000119312525201840/0001193125-25-201840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000119312525201840/alks-20250912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-201840
- JSON: https://secwatch.observer/filing/0001193125-25-201840.json
- Plain text: https://secwatch.observer/filing/0001193125-25-201840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.